- Home
- PHR vs IMCR Comparison
PHR vs IMCR Comparison
Compare PHR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHR
- IMCR
- Stock Information
- Founded
- PHR 2005
- IMCR 2008
- Country
- PHR United States
- IMCR United Kingdom
- Employees
- PHR N/A
- IMCR N/A
- Industry
- PHR Business Services
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHR Consumer Discretionary
- IMCR Health Care
- Exchange
- PHR Nasdaq
- IMCR Nasdaq
- Market Cap
- PHR 1.6B
- IMCR 1.4B
- IPO Year
- PHR 2019
- IMCR 2021
- Fundamental
- Price
- PHR $25.98
- IMCR $29.58
- Analyst Decision
- PHR Strong Buy
- IMCR Buy
- Analyst Count
- PHR 13
- IMCR 12
- Target Price
- PHR $31.23
- IMCR $63.00
- AVG Volume (30 Days)
- PHR 586.9K
- IMCR 367.3K
- Earning Date
- PHR 03-12-2025
- IMCR 05-07-2025
- Dividend Yield
- PHR N/A
- IMCR N/A
- EPS Growth
- PHR N/A
- IMCR N/A
- EPS
- PHR N/A
- IMCR N/A
- Revenue
- PHR $419,813,000.00
- IMCR $310,202,000.00
- Revenue This Year
- PHR $14.67
- IMCR $18.97
- Revenue Next Year
- PHR $11.87
- IMCR $8.43
- P/E Ratio
- PHR N/A
- IMCR N/A
- Revenue Growth
- PHR 17.83
- IMCR 24.36
- 52 Week Low
- PHR $17.07
- IMCR $27.19
- 52 Week High
- PHR $30.53
- IMCR $66.00
- Technical
- Relative Strength Index (RSI)
- PHR 46.01
- IMCR 49.95
- Support Level
- PHR $26.93
- IMCR $28.92
- Resistance Level
- PHR $28.64
- IMCR $30.04
- Average True Range (ATR)
- PHR 1.41
- IMCR 1.49
- MACD
- PHR 0.13
- IMCR 0.10
- Stochastic Oscillator
- PHR 54.68
- IMCR 53.71
About PHR Phreesia Inc.
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.